WuXi Biologics market cap is $511.5 b, and annual revenue was ¥5.61 b in FY 2020

WuXi Biologics Revenue growth (FY, 2019 - FY, 2020), %41%

WuXi Biologics Gross profit (FY, 2020)2.5 B

WuXi Biologics Gross profit margin (FY, 2020), %45.1%

WuXi Biologics Net income (FY, 2020)1.7 B

WuXi Biologics Cash, 31-Dec-20207.1 B

WuXi Biologics EV507.8 B

WuXi Biologics revenue was ¥5.61 b in FY, 2020 which is a 40.9% year over year increase from the previous period.

WuXi Biologics revenue breakdown by geographic segment: 43.9% from PRC, 44.2% from North America, 8.0% from Europe and 4.0% from Other

CNY | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 |
---|---|---|---|---|

## Revenue | 1.6b | 2.5b | 4.0b | 5.6b |

| 57% | 57% | 41% | |

## Cost of goods sold | 958.3m | 1.5b | 2.3b | 3.1b |

## Gross profit | 660.6m | 1.0b | 1.7b | 2.5b |

| 41% | 40% | 42% | 45% |

## Sales and marketing expense | 27.6m | 42.4m | 77.1m | 94.4m |

## R&D expense | 74.5m | 169.3m | 259.7m | 303.7m |

## General and administrative expense | 134.0m | 227.7m | 367.3m | 511.4m |

## Operating expense total | 252.3m | 439.4m | 704.0m | 909.6m |

## Interest expense | 35.7m | 19.6m | 42.7m | |

## Pre tax profit | 303.7m | 737.7m | 1.1b | 2.0b |

## Income tax expense | 51.1m | 107.3m | 116.3m | 273.1m |

## Net Income | 252.6m | 630.5m | 1.0b | 1.7b |

## EPS | 0.2 | 0.5 | 0.8 | 0.4 |

CNY | H1, 2018 | H1, 2019 | H1, 2020 |
---|---|---|---|

## Revenue | 1.1b | 1.6b | 1.9b |

## Cost of goods sold | 639.7m | 936.1m | 1.2b |

## Gross profit | 414.7m | 671.0m | 787.3m |

| 39% | 42% | 40% |

## Sales and marketing expense | 19.9m | 26.3m | 48.5m |

## R&D expense | 56.2m | 109.1m | 124.4m |

## General and administrative expense | 87.1m | 149.7m | 203.4m |

## Operating expense total | 163.2m | 285.2m | 376.3m |

## Interest expense | 4.6m | 22.4m | |

## Pre tax profit | 285.1m | 512.0m | 705.1m |

## Income tax expense | 35.5m | 62.6m | (25.6m) |

## Net Income | 249.6m | 449.5m | 730.7m |

## EPS | 0.2 | 0.3 | 0.5 |

CNY | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 |
---|---|---|---|---|

## Cash | 503.9m | 4.1b | 6.2b | 7.1b |

## Accounts Receivable | 314.3m | 762.9m | 1.3b | 2.3b |

## Prepaid Expenses | 927.0k | 3.2m | 4.1m | 6.6m |

## Inventories | 135.5m | 227.2m | 399.4m | 1.1b |

## Current Assets | 3.0b | 5.7b | 9.7b | 14.2b |

## PP&E | 1.8b | 2.9b | 6.3b | 12.0b |

## Goodwill | 185.4m | 185.4m | ||

## Total Assets | 4.8b | 9.4b | 17.6b | 29.0b |

## Accounts Payable | 137.3m | 221.0m | 185.8m | 646.0m |

## Short-term debt | 532.6m | 827.8m | ||

## Current Liabilities | 798.1m | 1.3b | 2.9b | 4.5b |

## Long-term debt | 1.7b | 2.5b | ||

## Non-Current Liabilities | 26.5m | 80.2m | 1.8b | 3.6b |

## Total Debt | 2.2b | 3.3b | ||

## Total Liabilities | 824.6m | 1.4b | 4.7b | 8.1b |

## Common Stock | 192.0k | 202.0k | 214.0k | 225.0k |

## Additional Paid-in Capital | 3.4b | 6.7b | 10.3b | |

## Retained Earnings | 394.2m | 962.2m | 1.9b | |

## Total Equity | 4.0b | 8.0b | 12.9b | 20.9b |

## Debt to Equity Ratio | 0.2 x | 0.2 x | ||

## Debt to Assets Ratio | 0.1 x | 0.1 x | ||

## Financial Leverage | 1.2 x | 1.2 x | 1.4 x | 1.4 x |

CNY | H1, 2018 | H1, 2019 | H1, 2020 |
---|---|---|---|

## Cash | 4.4b | 2.9b | 3.7b |

## Accounts Receivable | 576.7m | 872.0m | 1.7b |

## Prepaid Expenses | 8.2m | 7.2m | 7.1m |

## Inventories | 243.3m | 318.9m | 611.8m |

## Current Assets | 5.8b | 5.0b | 9.4b |

## PP&E | 2.2b | 3.6b | 9.1b |

## Goodwill | 185.4m | ||

## Total Assets | 8.6b | 10.2b | 20.7b |

## Accounts Payable | 142.2m | 250.7m | 355.4m |

## Short-term debt | 31.5m | 827.9m | |

## Current Liabilities | 990.2m | 1.3b | 3.2b |

## Long-term debt | 216.6m | 2.9b | |

## Non-Current Liabilities | 69.0m | 319.1m | 3.8b |

## Total Debt | 248.1m | 3.7b | |

## Total Liabilities | 1.1b | 1.7b | 6.9b |

## Common Stock | 201.0k | 204.0k | 216.0k |

## Additional Paid-in Capital | 6.6b | 6.7b | 10.3b |

## Retained Earnings | 636.2m | 1.4b | 2.6b |

## Total Equity | 7.5b | 8.5b | 13.8b |

## Debt to Equity Ratio | 0 x | 0.3 x | |

## Debt to Assets Ratio | 0 x | 0.2 x | |

## Financial Leverage | 1.1 x | 1.2 x | 1.5 x |

CNY | FY, 2017 | FY, 2018 | FY, 2019 |
---|---|---|---|

## Depreciation and Amortization | 122.7m | 145.9m | 224.4m |

## Accounts Receivable | (203.1m) | (452.5m) | (643.9m) |

## Inventories | (138.9m) | (95.7m) | (94.0m) |

## Accounts Payable | 203.9m | 183.5m | 579.6m |

## Cash From Operating Activities | 360.3m | 761.6m | 1.2b |

## Purchases of PP&E | (670.6m) | (1.3b) | (3.2b) |

## Cash From Investing Activities | (2.2b) | (416.1m) | (4.5b) |

## Long-term Borrowings | (1.2b) | (162.2m) | |

## Cash From Financing Activities | 2.2b | 3.2b | 5.4b |

## Net Change in Cash | 334.8m | 3.6b | 2.1b |

## Interest Paid | 36.3m | 49.8m | |

## Income Taxes Paid | 43.3m | 52.1m | 78.0m |

CNY | FY, 2017 |
---|---|

## Revenue/Employee | 636.6k |

## Financial Leverage | 1.2 x |

WuXi Biologics's Backlog was reported to be $11.3b in FY, 2020.

FY, 2017 | H1, 2018 | FY, 2018 | H1, 2019 | FY, 2019 | H1, 2020 | Oct, 2020 | FY, 2020 | |
---|---|---|---|---|---|---|---|---|

## Pre-clinical Projects | 90 | 98 | 97 | 106 | 121 | 141 | 161 | 169 |

## Backlog | $1.48 b | $1.78 b | $3.6 b | $5.1 b | $10.3 b | $11.32 b | ||

## Backlog (Upcoming Potential Milestone Fees) | $1 b | $1.25 b | $2.01 b | $3.42 b | $3.93 b | $4.7 b | ||

## Commercial Manufacturing Projects | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 |

## Early-phase Projects | 62 | 78 | 94 | 102 | 112 | 125 | 127 | 135 |

## Integrated Projects | 161 | 187 | 205 | 224 | 250 | 286 | 312 | 334 |

## Late-phase Projects | 8 | 10 | 13 | 15 | 16 | 19 | 23 | 28 |

## New Projects | 57 | 59 | 72 | |||||

## Phase I Projects | 68 | 75 | 85 | 93 | 93 | 103 | ||

## Phase II Projects | 26 | 27 | 27 | 32 | 34 | 32 | ||

## Service Backlog | $476 m | $534 m | $1.63 b | $1.69 b | $6.3 b | $6.63 b |

WuXi Biologics's employees are reported to be approximately 55% female and 45% male.

FY, 2019 | FY, 2018 | FY, 2017 | |
---|---|---|---|

Female | 54.8% | 54.8% | 54.5% |

Male | 45.2% | 45.2% | 45.5% |